Phase III MIRROR trial of Krystexxa meets primary endpoint in chronic gout – Horizon Therapeutics
Horizon Therapeutics announced topline results of the phase III MIRROR trial met the primary endpoint, showing a significant increase in efficacy using Krystexxa (pegloticase injection) with the immunomodulator… read more.
